

**Petition For Revival Of An Application For Patent Abandoned  
Unintentionally Under 37 CFR 1.137(b) (Large Entity)**

Docket No.  
**RLL-5.4DIVUS**

In Re Application Of: **ANAND et al.**

Serial No.  
**09/578,239**

Filing Date  
**May 24, 2000**

Examiner  
**Wright, Sonya N.**

Group Art Unit  
**1626**

Invention: **1-(4-ARYLPIPERAZIN-1-YL)-OMEGA-[N-(ALPHA,OMEGA-DICARBOXIMIDO)]-ALKANES  
USEFUL AS URO-SELECTIVE ALPHA1-ADRENOCEPTOR BLOCKERS**



**ASSISTANT COMMISSIONER FOR PATENTS**  
**Attention: Office of Petitions**  
**Box DAC**  
**Washington, D.C. 20231**

**NOTE:** If information or assistance is needed in completing this form, please contact Petitions Information at (703) 305-9282.

The above-identified application became abandoned for failure to file a timely and proper response to a notice or action by the Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extension of time actually obtained.

**APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION**

**NOTE:** A grantable petition requires the following items:

- (1) Petition fee;
- (2) Reply and/or issue fee;
- (3) Terminal disclaimer with disclaimer fee--required for all utility and plant applications filed before June 8, 1995; and for all design applications; and
- (4) Statement that the entire delay was unintentional.

1. ☒ A proposed reply to the above-identified notice or action:

☒ is enclosed. ☐ was filed on \_\_\_\_\_

The proposed reply is in the form of: **Request for Continued Examination and Submission**

2. ☐ The issue fee:

☐ is enclosed. ☐ was paid on \_\_\_\_\_

**RECEIVED**

**NOV 07 2002**

3. ☐ The abandoned application was a:

☐ design application. ☒ utility application. ☐ plant application.

**OFFICE OF PETITIONS**

4. ☐ A terminal disclaimer (and fee) disclaiming a period equivalent to the period of abandonment is enclosed.

5. ☒ Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.

11/05/2002 CNGUYEN 00000113 500912 09578239

01 FC-1452 1200.00 CH

**Petition For Revival Of An Application For Patent Abandoned  
Unintentionally Under 37 CFR 1.137(b) (Large Entity)**

Docket No.  
**RLL-5.4DIVUS**

In Re Application Of: **ANAND et al.**

Serial No.  
**09/578,239**

Filing Date  
**May 24, 2000**

Examiner  
**Wright, Sonya N.**

Group Art Unit  
**1626**

Invention: **1-(4-ARYLPIPERAZIN-1-YL)-OMEGA-[N-(ALPHA,OMEGA-DICARBOXIMIDO)]-ALKANES  
USEFUL AS URO-SELECTIVE ALPHA1-ADRENOCEPTOR BLOCKERS**

**Calculation and Payment of Fees**

Enclosed are the following fees:

6. ☒ Petition fee under 37 CFR 1.17(m) in the amount of: \$1,280.00
7. ☐ Fee for amendment in the amount of: \_\_\_\_\_
8. ☐ Fee for extension of time to respond to Office Action in the amount of: \_\_\_\_\_
9. ☐ Issue fee in the amount of: \_\_\_\_\_
10. ☐ Continuing application filing fee in the amount of: \_\_\_\_\_
11. ☐ Terminal disclaimer fee in the amount of: \_\_\_\_\_
12. ☐ \_\_\_\_\_
- Total fees enclosed: \$1,280.00

The fee of **\$1,280** is to be paid as follows:

- ☒ A check in the amount of the fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account No. **50-0912**
- A duplicate copy of this sheet is enclosed.

**RECEIVED**

**NOV 07 2002**

**OFFICE OF PETITIONS**

Petition For Revival Of An Application For Patent Abandoned  
Unintentionally Under 37 CFR 1.137(b) (Large Entity)

Docket No.  
RLL-5.4DIVUS

In Re Application Of: ANAND et al.


Serial No.  
09/578,239

Filing Date  
May 24, 2000

Examiner  
Wright, Sonya N.

Group Art Unit  
1626

Invention: 1-(4-ARYLPIPERAZIN-1-YL)-OMEGA-[N-(ALPHA,OMEGA-DICARBOXIMIDO)]-ALKANES  
USEFUL AS URO-SELECTIVE ALPHA1-ADRENOCEPTOR BLOCKERS



Statement

The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.

  
Signature

Dated: October 28, 2002

George E. Heibel, Ph.D.  
Reg. No. 42,648  
Ranbaxy Laboratories Limited  
600 College Road East, Suite 2100  
Princeton, New Jersey 08540  
Telephone: (609) 720-5608  
Facsimile: (609) 720-9779


RECEIVED

NOV 07 2002

OFFICE OF PETITIONS

CC:

I certify that this document and fee is being deposited  
on October 28, 2002 with the U.S. Postal Service as  
first class mail under 37 C.F.R. 1.8 and is addressed to the  
Assistant Commissioner for Patents, Washington, D.C.  
20231.

  
Signature of Person Mailing Correspondence

Christine Kenedy

Typed or Printed Name of Person Mailing Correspondence